REG-4basebio Plc: Neomatrix Product Supply Agreement

4BasebioAnnouncement

25/05/2023 07:00

25 May 2023

4basebio PLC

("4basebio", the "Company" or the “Group”)

4basebio and Neomatrix announce clinical material supply agreement to develop
personalised cancer therapy utilising 4basebio’s proprietary hpDNA™.

Cambridge, UK , 25 May 2023 – 4basebio PLC (AIM: 4BB), an innovation driven
biotechnology company enabling and accelerating development of advanced
therapy medicinal products (ATMPs) through its high performant synthetic DNA
products and non-viral, cell targeting nucleic acid delivery platform, today
announces a product supply agreement with Neomatrix, an Italian based biotech
company focused on personalised cancer immunotherapies.

Under the agreement, 4basebio will supply clinical and preclinical DNA
materials into Neomatrix’ neoantigen cancer vaccine program. The program is
expected to start patient enrolment in early 2024.  Neomatrix will gain
access to 4basebio‘s proprietary DNA products including hpDNA™ and
oeDNA™. 4basebio will manufacture and provide the personalised clinical
grade DNA products, the key component in Neomatrix’ immunotherapy cancer
treatment.

Neomatrix’ vaccine based cancer treatment utilises the patient’s immune
system to recognise newly generated antigens (neoantigens), created by and
displayed on tumour cells. Personalised cancer vaccines require a tumour
biopsy which is sequenced to identify the neoantigens created by
cancer-specific DNA mutations. A patient specific DNA sequence coding for such
neoantigens is then designed, produced and administered. The time between
initial biopsy and vaccine administration (“needle to needle”) is
critical. 4basebio’s enzymatically produced synthetic DNA, with its rapid
manufacturing timescales, is uniquely positioned to provide high performant
DNA products in a timely fashion.

Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: “We are delighted to be
working with Neomatrix in the delivery of neoantigen cancer vaccines.
4basebio’s DNA products offer significant advantages both in terms of
performance and the time required to manufacture a personalised vaccine, which
is particularly relevant where needle to needle time is paramount to clinical
outcome.”

Luigi Aurisicchio, CEO of Neomatrix, said: “We are excited to have 4basebio
as our partner for the production of our personalised neoantigen vaccines. The
performance and quality of 4basebio’s DNA products as well as the speed of
manufacture have driven our decision to partner with 4basebio.”

For further enquiries, please contact:

4basebio PLC                                  
                      +44 (0)12 2396 7943

Heikki Lanckriet

Nominated Adviser                                   
            +44 (0)20 7213 0880
Cairn Financial Advisers LLP
Jo Tuner / Sandy Jamieson

Broker                                        
                            +44 (0)20 7220 0500
finnCap Ltd
Geoff Nash / Richard Chambers / Charlotte Sutcliffe

Lionsgate Communications (Media Enquiries)  +44 (0)77 91892509
Jonathan Charles

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company
focussed on accelerating the development of advanced therapy medicinal
products (ATMPs) through its high performant synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The Company’
objective is to become a market leader in the manufacture and supply of high
quality synthetic DNA products for research, therapeutic and pharmacological
use as well as development of target specific non-viral vectors for the
efficient delivery of payloads in patients. The company is offering GMP
compliant DNA starting materials suitable for use in AAV viral vector
production as well as mRNA vaccine and therapeutics production.

About Neomatrix

Neomatrix is a biotech company with more than 15 years of experience and
proven expertise in drug discovery in oncology and is recognised for the
design and implementation of a number of innovative technologies, including
that of DNA gene therapy. Neomatrix’ core expertise is its experience in the
prediction of neoantigens with an electroporation delivery system, a
technology that can be used for a variety of clinically useful applications,
from vaccine development to somatic gene therapy.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
the 4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved